Skip to content

Study · Randomized controlled trial · n = 21 · 2011

6 results

Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.

Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M

Journal of clinical pharmacology12 Jan 2011Cited by 25 (Europe PMC)

PMID21228406 (opens in a new tab)DOI10.1177/0091270010389471 (opens in a new tab)PepBankPUB-21228406
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, liraglutide did not change ethinyl estradiol exposure: the AUC ratio was 1.06 (90% CI 0.99-1.13), within the equivalence limits.

    In plain wordsIn healthy postmenopausal women, liraglutide did not change how much ethinyl estradiol from a contraceptive pill reached the blood.

    Peptide
    Liraglutide
    Outcome
    No significant changeEthinyl estradiol AUC ratio (liraglutide versus placebo)
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The 90% confidence interval (CI) of the ratio of the area under the curve (AUC) (1.06; 90% CI, 0.99-1.13) for ethinyl estradiol (during liraglutide and placebo) was within defined limits, demonstrating equivalence.
    2 context sentences
    Summary · context
    Postmeno-pausal healthy women (n = 21) were included.
    Summary · context
    Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, levonorgestrel AUC was 18% greater with liraglutide than with placebo (ratio 1.18; 90% CI 1.04-1.34), outside the equivalence limits.

    In plain wordsIn healthy postmenopausal women, liraglutide raised the levonorgestrel exposure from a contraceptive pill by 18% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseLevonorgestrel AUC ratio (liraglutide versus placebo)
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The 90% CI for the ratio of AUC for levonorgestrel was not fully contained within the limits (1.18; 90% CI, 1.04-1.34) (levonorgestrel AUC was 18% greater with liraglutide vs placebo).
    2 context sentences
    Summary · context
    Postmeno-pausal healthy women (n = 21) were included.
    Summary · context
    Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, equivalence was shown for levonorgestrel AUC(0-t) with liraglutide versus placebo (ratio 1.15; 90% CI 1.06-1.24).

    In plain wordsIn healthy postmenopausal women, a second measure of levonorgestrel exposure stayed within the equivalence limits with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeLevonorgestrel AUC(0-t) ratio (liraglutide versus placebo)
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, equivalence was demonstrated for levonorgestrel AUC(0-t) (1.15; 90% CI, 1.06-1.24).
    2 context sentences
    Summary · context
    Postmeno-pausal healthy women (n = 21) were included.
    Summary · context
    Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, ethinyl estradiol Cmax was 12% lower with liraglutide than with placebo, and equivalence was not demonstrated.

    In plain wordsIn healthy postmenopausal women, liraglutide lowered the peak ethinyl estradiol level by 12% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseEthinyl estradiol maximum concentration (Cmax)
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Equivalence was not demonstrated for maximum concentration (C(max)); values for ethinyl estradiol and levonorgestrel C(max) were 12% and 13% lower with liraglutide versus placebo, respectively.
    2 context sentences
    Summary · context
    Postmeno-pausal healthy women (n = 21) were included.
    Summary · context
    Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, levonorgestrel Cmax was 13% lower with liraglutide than with placebo, and equivalence was not demonstrated.

    In plain wordsIn healthy postmenopausal women, liraglutide lowered the peak levonorgestrel level by 13% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLevonorgestrel maximum concentration (Cmax)
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Equivalence was not demonstrated for maximum concentration (C(max)); values for ethinyl estradiol and levonorgestrel C(max) were 12% and 13% lower with liraglutide versus placebo, respectively.
    2 context sentences
    Summary · context
    Postmeno-pausal healthy women (n = 21) were included.
    Summary · context
    Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments.
  6. 06HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, ethinyl estradiol and levonorgestrel both reached Cmax about 1.5 hours later with liraglutide than with placebo.

    In plain wordsIn healthy postmenopausal women, the contraceptive hormones reached their peak about 1.5 hours later with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseTime to maximum concentration of ethinyl estradiol and levonorgestrel
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both reached C(max) ~1.5 hours later with liraglutide.
    2 context sentences
    Summary · context
    Postmeno-pausal healthy women (n = 21) were included.
    Summary · context
    Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.